An innovative research on pediatric cancer diagnosis was presented at the establishment event of the NICHOLAS ZOE FOUNDATION (NZF) in Miami, Florida on March 15th.

The NZF foundation, in memory of Nicholas Artemiou, announced financial support for the research program that will significantly contribute to the diagnosis and treatment of pediatric cancer. The foundation's goal will be to support research programs for effective diagnosis and treatment of Ewing's sarcoma and other pediatric solid tumors, as well as awareness and education for early diagnosis of these tumors.

According to the results of a research program, led by Dr. Mark Fleming, Director of the Pathology Department at Boston Children's Hospital, with a specific methodology involving blood examination and other biological fluid analysis with DNA profiling, treatment for pediatric solid tumors such as Ewing's sarcoma, Neuroblastoma, and Rhabdomyosarcoma will be selected, tumors that have presented high mortality rates up until today. The institute where the aforementioned research program is being developed is globally top-ranked for its level of research against pediatric cancer.

Alexia Potamitou, President of the NICHOLAS ZOE FOUNDATION, and mother of Nicholas Artemiou, mentioned in her speech, "With the financial support of this research program, we aim to contribute to the development of simple tests that can timely diagnose the tumor, monitor response to treatment, and recognize disease recurrence."

Dr. Mark Fleming mentioned in his speech, "This study, which is in its final stages and shortly before clinical application, will enable the selection of appropriate personalized treatment based on the genetic characteristics of pediatric solid tumors. With the financial support of NZF, it will be possible to monitor patients without performing invasive biopsies and radiological examinations regardless of tumor location, which will be achievable with a simple blood test." He added that NZF, through its establishment and activities, will raise financial resources to continue and complete the research program, making Nicholas Artemiou's desire and wish a reality - "that no other child will experience the days of pain he lived through."

 

 

 

 

View this post on Instagram

 

 

 

 

 

 

 

 

 

 

 

A post shared by Nicholas Zoe Foundation (@nicholaszoefoundation)

For more information, please visit: www.nicholaszoefoundation.com